Berenberg cuts target price for Synthomer, but stays at 'buy'
Shares in were trading lower on Tuesday after Berenberg lowered its target price for the chemicals stock on the back of a subdued market outlook.
Nevertheless, the broker kept a 'buy' rating on shares with its new target price of 230p (down from 265p) still indicating significant upside from current levels.
"2025 will be a case of gradual, hard-won improvements for Synthomer, in our view. On the positive side, nitrile markets seem set for higher profitability yoy. Self-help measures should account for the largest single portion of earnings growth in 2025. Covenant risk also appears manageable," Berenberg said in a research note.
"However, the picture is more subdued for end-demand, partly because of 'higher-for-longer rates' in the US."
The broker highlighted a recent profit warning from US adhesives manufacturer HB Fuller, which cited order delays and headwinds from higher European gas prices.
While new trade tariffs proposed by Donald Trump could ease competition for Synthomer's Eastman adhesives resins business - which generates half of its sales in North America - "the negative earnings trajectory of some likely end-customers in the US [...] suggests that the demand outlook may take a few months to respond to any tax cuts or deregulation under the incoming Trump administration", Berenberg said.
Synthomer's share price was down 4% at 145.28p by 1042 GMT.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.